WIKIFARMER
23.6.2022 10:02:13 CEST | Business Wire | Press release
Wikifarmer , a global platform with the mission of empowering farmers through educating them and offering them access to the open market to sell their products at fair prices and mentioned as the “Wikipedia of Farming” by the FAO of the UN, has successfully completed a Seed financing round with the support of a group of world class investors such as Mathias Kamprad, Inter IKEA BoD, Patrick and Cynthia Odier of the Lombard Odier Private Bank, Sophia Bendz, venture capitalist and former Spotify global director of marketing, Alexandre Vilgrain, C.E.O. of SOMDIAA group, the Constantakopoulos foundation and with the participation of Metavallon Venture Capital, a leading Greek VC firm.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220621005694/en/
Agriculture is still one of the least digitized industries in the world and this has not allowed the industry’s value chain to be disrupted, but instead has created a paradox; farmers are the most valuable part of agriculture’s value chain but make the least profit out of it. In addition to that, most farmers are still using the techniques of their ancestors to grow their crops. The need for up-to-date sustainable agriculture knowledge has never been greater in the world than today. Agriculture & food trade market is expected to exceed 6 trillion EUR in value by the end of 2025.
Wikifarmer’s platform allows farmers to access free up to date knowledge on agricultural best practices and gives them the opportunity to sell their products directly to businesses, helping them minimize or surpass the large number of intermediaries that currently exist. Wikifarmer is aiming to become the universal source for farmers searching for information and the go-to destination for people seeking to purchase agricultural products globally.
Co-founders Ilias Sousis, Peter Sagos and Harry Parianos were inspired by the negative impact that outdated practices in agriculture have on the environment, global hunger and the financial sustainability of farmers. At the same time, helping farmers make a higher profit margin out of their commercial activities will have a wider impact on the economy and on the quality of products produced.
Sousis has been a part of the management team of Google Greece for years, leading the commercial launch of YouTube in Greece and Cyprus and has had prior entrepreneurial experience in traditional commerce, while Sagos is a passionate agronomist with deep knowledge in agricultural production and a business background as he was running a seeds trading family business. Parianos is the owner and CEO of McCann Athens and has spent more than 30 years as a senior leader in the advertising industry.
Wikifarmer’s library and marketplace has already been visited by 12 million visitors from more than 200 countries while 30,000 products have been uploaded by farmers. More than 5,000 buyers - including food processing units (FMCGs, Food services, etc), Wholesalers/ Importers, Retail Stores and Hotels/Restaurants - have purchased a product directly from a farm.
The investment will be used to expand the educational content to 20 languages and to enhance Wikifarmer’s marketplace presence in Greece, Italy, France and Spain, with the objective to create a Mediterranean hub of farmers that will attract buyers from all over the world, establishing the platform in a leading place globally.
Sagos said: “We want to democratize agriculture, give farmers around the world the chance to learn new things and thus the opportunity to grow their capabilities, their crops, their earnings. This is the only way forward to make this sector more sustainable and feed the growing world population.”
Ilias Sousis, mentioned regarding the raise: “I am thrilled that a group of very important and sustainability-conscious world-class investors are sharing our vision and efforts to solve some of the biggest pain points that have troubled the sector of agriculture for hundreds of years now.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005694/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
